retatrutide triple agonist obesity trial 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

GIP receptor activation enhances insulin sensitivity and may have direct effects on fat tissue

A Sharps Container: Proper disposal of used needles is a fundamental lab safety practice

When activated alongside GLP-1, glucagon receptor stimulation drives thermogenesis (heat production from calorie burning), accelerates fatty acid oxidation, and increases resting metabolic rate

In selected patients, surgical options used in post-bariatric contextssuch as facelifts and neck liftsmay be appropriate

The rise of the incretin therapies for obesity has attracted tremendous interest, both from drug developers and prospective patients (consumers)

I am *never* without at least one box of pimple patches in my skincare cabinet This Isnt What You Think No pills